Search Results - "Korse, C M"

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial by Borgers, J S W, Burgers, F H, Terveer, E M, van Leerdam, M E, Korse, C M, Kessels, R, Flohil, C C, Blank, C U, Schumacher, T N, van Dijk, M, Henderickx, J G E, Keller, J J, Verspaget, H W, Kuijper, E J, Haanen, J B A G

“…The gut microbiome plays an important role in immune modulation. Specifically, presence or absence of certain gut bacterial taxa has been associated with…”
Get full text

A real or apparent decrease in glomerular filtration rate in patients using olaparib? by Bruin, M. A. C., Korse, C. M., van Wijnen, B., de Jong, V. M. T., Linn, S. C., van Triest, B., Rosing, H., Beijnen, J. H., van den Broek, D., Huitema, A. D. R.

“…Purpose Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for ovarian and metastatic breast cancer. Increased serum creatinine levels have…”
Get full text

Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours by Korse, C M, Muller, M, Taal, B G

“…Background: The aim of this prospective study was to examine whether discontinuation of proton pump inhibitors (PPIs) or replacement by H 2 -receptor…”
Get full text

Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer by Stiekema, A, Lok, CAR, Korse, CM, van Driel, WJ, van der Noort, V, Kenter, GG, Van de Vijver, KK

“…The extent of surgery and the decision for adjuvant treatment in patients with endometrial cancer (EC) depend on the presence of risk factors for lymph node…”
Get full text

An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival by Korse, C.M., Taal, B.G., Bonfrer, J.M.G., Vincent, A., van Velthuysen, M.L., Baas, P.

“…Progastrin-releasing peptide (proGRP) is a recently identified biomarker of small-cell lung cancer. In well-differentiated neuroendocrine tumours (WDNETs),…”
Get full text

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models by Vermaat, J.S., van der Tweel, I., Mehra, N., Sleijfer, S., Haanen, J.B., Roodhart, J.M., Engwegen, J.Y., Korse, C.M., Langenberg, M.H., Kruit, W., Groenewegen, G., Giles, R.H., Schellens, J.H., Beijnen, J.H., Voest, E.E.

“…In metastatic renal cell cancer (mRCC), the Memorial Sloan-Kettering Cancer Center (MSKCC) risk model is widely used for clinical trial design and patient…”
Get full text

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Baudin, E., Caplin, M., Garcia-Carbonero, R., Fazio, N., Ferolla, P., Filosso, P.L., Frilling, A., de Herder, W.W., Hörsch, D., Knigge, U., Korse, C.M., Lim, E., Lombard-Bohas, C., Pavel, M., Scoazec, J.Y., Sundin, A., Berruti, A.

“…•This updated ESMO Clinical Practice Guideline provides key recommendations on the management of lung and thymic carcinoids.•Characterisation is best…”
Get full text

Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease by ZUETENHORST, J. M, KORSE, C. M, BONFRER, J. M. G, BAKKER, R. H, TAAL, B. G

“…Carcinoid heart disease (CHD) occurs in 20-70% of the patients with metastatic well-differentiated neuroendocrine tumours (NET). We evaluated whether…”
Get full text

Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines by Vermeulen, R. F. M., Korse, C. M., Kenter, G. G., Brood-van Zanten, M. M. A., Beurden, M. van

“…Background: Women at high risk to develop ovarian cancer opt for risk-reducing salpingo-oophorectomy (RRSO) to reduce the risk by 80-96%. RRSO leads to a…”
Get full text

The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma by BONFRER, J. M. G, KORSE, C. M, NIEWEG, O. E, RANKIN, E. M

“…In this study we measured S-100B using a recently developed luminometric immunoassay with a detection limit of 0.02 microg l(-1). By measuring serum S-100B…”
Get full text

Impact of risk-reducing salpingo-oophorectomy in premenopausal women by Vermeulen, R. F. M., Beurden, M. van, Korse, C. M., Kenter, G. G.

“…Objectives: To describe implications of premenopausal risk-reducing salpingo-oophorectomy (RRSO) on quality of life, endocrine symptoms, sexual function,…”
Get full text

Impact of risk-reducing salpingo-oophorectomy on lipid determinants, HbA1c and CRP by Vermeulen, R. F. M., van Altena, J. L., Gaarenstroom, K. N., van Beurden, M., Kieffer, J. K., Aaronson, N. K., Kenter, G. G., Korse, C. M.

“…Risk-reducing salpingo-oophorectomy (RRSO) is advised before 40-45 years of age for BRCA1/2 mutation carriers. This study describes the effect of RRSO on lipid…”
Get full text

Corrigendum to “Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 32 (2021) 439–451] by Baudin, E., Caplin, M., Garcia-Carbonero, R., Fazio, N., Ferolla, P., Filosso, P.L., Frilling, A., de Herder, W.W., Hörsch, D., Knigge, U., Korse, C.M., Lim, E., Lombard-Bohas, C., Pavel, M., Scoazec, J.Y., Sundin, A., Berruti, A.

Get full text

Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital? by Lof, P., van de Vrie, R., Korse, C.M., van Gent, M.D.J.M., Mom, C.H., Rosier - van Dunné, F.M.F., van Baal, W.M., Verhoeve, H.R., Hermsen, B.B.J., Verbruggen, M.B., Hemelaar, M., van de Swaluw, A.M.G., Knipscheer, H.C., Huirne, J.A.F., Westenberg, S.M., van der Noort, V., Amant, F., van den Broek, D., Lok, C.A.R.

“…The value of serum human epididymis protein 4 (HE4) in guiding referral decisions in patients with an ovarian mass remains unclear, because the majority of…”
Get full text

Diagnostic validation and interpretation of longitudinal circulating biomarkers using a biomarker response characteristic plot by Moritz, R., Muller, M., Korse, C.M., van den Broek, D., Baas, P., van den Noort, V., ten Hoeve, J.J., van den Heuvel, M.M., van Rossum, H.H.

“…Serum-based tumor biomarkers are used to monitor cancer treatment, while clear guidance on the clinical usage is often lacking. We describe a graphical…”
Get full text

Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma by Hamberg, A P, Korse, C M, Bonfrer, J M, de Gast, G C

“…Serum S100B and lactate dehydrogenase (LDH) levels were evaluated for their ability to predict response in patients with metastatic malignant melanoma and to…”
Get full text

Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin by Stiekema, A, Boldingh, Q.J.A.J, Korse, C.M, van der Noort, V, Boot, H, van Driel, W.J, Kenter, G.G, Lok, C.A.R

“…Abstract Objective About 5–15% of all malignant ovarian tumors are metastases from other malignancies such as gastrointestinal tumors, breast cancer or…”
Get full text

A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer by Stiekema, A, Lok, C.A.R, Kenter, G.G, van Driel, W.J, Vincent, A.D, Korse, C.M

“…Abstract Objective Ovarian cancer is the leading cause of death in women with gynecologic cancer. CA125 is the commonly used biomarker in the diagnosis of…”
Get full text

Comparison of four different assays for determination of serum S-100B by SMIT, L. H. M, KORSE, C. M, BONFRER, J. M. G

“…S-100B determination has been shown to be clinically useful in the management of melanoma patients. After the development of a test for determination of the…”
Get full text

Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study by Vermeulen, R. F. M., van Beurden, M., Gaarenstroom, K. N., Teunis, T., Kieffer, J. M., Aaronson, N. K., Kenter, G. G., Korse, C. M.

“…Objectives: The aim of this study was to investigate whether serum anti-Müllerian hormone (AMH) predicts symptom burden after risk-reducing…”
Get full text